Primary refractory and relapsed adult acute lymphoblastic leukemia

Characteristics, treatment results, and prognosis with salvage therapy

Deborah A. Thomas, Hagop Kantarjian, Terry L. Smith, Charles Koller, Jorge Cortes, Susan O'Brien, Francis J. Giles, James Gajewski, Sherry Pierce, Michael J. Keating

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

BACKGROUND. Relapses continue to be problematic for adults with acute lymphoblastic leukemia (ALL). New therapies generally are first tested in the salvage setting prior to incorporation into frontline regimens. Defining the prognosis at relapse (or at failure of induction) and subsequently predicting outcome would be useful to select the population in whom to test new strategies, rather than attempting traditional reinduction therapy. METHODS. Between March 1980 and March 1997, 314 eligible adults with primary refractory (24%) or primary relapsed (76%) ALL were treated with various chemotherapy or stem cell transplantation (SCT) regimens. The Cox proportional hazards model was used to assess biologic factors and disease history in relation to survival. RESULTS. A complete remission (CR) was achieved in 97 patients (31%), 21% died prior to a response, and 49% were refractory to salvage therapy. Of the 76 patients refractory to induction therapy for their de novo ALL, 26 patients (34%) achieved a CR with salvage therapy. The median overall CR duration was 6 months. The median overall survival was 5 months; 24% of the patients were alive at 1 year, and the projected survival at 5 years was 3%. Nineteen patients were alive at the time of last follow-up, 10 with 6 weeks to 10 years of continuous CR from the time of their first salvage therapy. SCT consolidation in second CR was performed in 25% of patients; 28% of those who received allogeneic SCT remain in continuous CR at 4 months, 2 1/2 years, 3 1/2 years, and 10 years, whereas all 8 who received autologous SCT have relapsed. Favorable factors for longer survival by multivariate analysis were age

Original languageEnglish (US)
Pages (from-to)1216-1230
Number of pages15
JournalCancer
Volume86
Issue number7
DOIs
StatePublished - Oct 1 1999
Externally publishedYes

Fingerprint

Salvage Therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Stem Cell Transplantation
Survival
Therapeutics
Recurrence
Biological Factors
Survival Analysis
Proportional Hazards Models
Multivariate Analysis
Drug Therapy
Population

Keywords

  • Acute lymphoblastic leukemia
  • Prognostic factors
  • Refractory
  • Relapse
  • Second induction
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Primary refractory and relapsed adult acute lymphoblastic leukemia : Characteristics, treatment results, and prognosis with salvage therapy. / Thomas, Deborah A.; Kantarjian, Hagop; Smith, Terry L.; Koller, Charles; Cortes, Jorge; O'Brien, Susan; Giles, Francis J.; Gajewski, James; Pierce, Sherry; Keating, Michael J.

In: Cancer, Vol. 86, No. 7, 01.10.1999, p. 1216-1230.

Research output: Contribution to journalArticle

Thomas, DA, Kantarjian, H, Smith, TL, Koller, C, Cortes, J, O'Brien, S, Giles, FJ, Gajewski, J, Pierce, S & Keating, MJ 1999, 'Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy', Cancer, vol. 86, no. 7, pp. 1216-1230. https://doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O
Thomas, Deborah A. ; Kantarjian, Hagop ; Smith, Terry L. ; Koller, Charles ; Cortes, Jorge ; O'Brien, Susan ; Giles, Francis J. ; Gajewski, James ; Pierce, Sherry ; Keating, Michael J. / Primary refractory and relapsed adult acute lymphoblastic leukemia : Characteristics, treatment results, and prognosis with salvage therapy. In: Cancer. 1999 ; Vol. 86, No. 7. pp. 1216-1230.
@article{1aae14915c244cc49fd37d8733c98dcf,
title = "Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy",
abstract = "BACKGROUND. Relapses continue to be problematic for adults with acute lymphoblastic leukemia (ALL). New therapies generally are first tested in the salvage setting prior to incorporation into frontline regimens. Defining the prognosis at relapse (or at failure of induction) and subsequently predicting outcome would be useful to select the population in whom to test new strategies, rather than attempting traditional reinduction therapy. METHODS. Between March 1980 and March 1997, 314 eligible adults with primary refractory (24{\%}) or primary relapsed (76{\%}) ALL were treated with various chemotherapy or stem cell transplantation (SCT) regimens. The Cox proportional hazards model was used to assess biologic factors and disease history in relation to survival. RESULTS. A complete remission (CR) was achieved in 97 patients (31{\%}), 21{\%} died prior to a response, and 49{\%} were refractory to salvage therapy. Of the 76 patients refractory to induction therapy for their de novo ALL, 26 patients (34{\%}) achieved a CR with salvage therapy. The median overall CR duration was 6 months. The median overall survival was 5 months; 24{\%} of the patients were alive at 1 year, and the projected survival at 5 years was 3{\%}. Nineteen patients were alive at the time of last follow-up, 10 with 6 weeks to 10 years of continuous CR from the time of their first salvage therapy. SCT consolidation in second CR was performed in 25{\%} of patients; 28{\%} of those who received allogeneic SCT remain in continuous CR at 4 months, 2 1/2 years, 3 1/2 years, and 10 years, whereas all 8 who received autologous SCT have relapsed. Favorable factors for longer survival by multivariate analysis were age",
keywords = "Acute lymphoblastic leukemia, Prognostic factors, Refractory, Relapse, Second induction, Treatment",
author = "Thomas, {Deborah A.} and Hagop Kantarjian and Smith, {Terry L.} and Charles Koller and Jorge Cortes and Susan O'Brien and Giles, {Francis J.} and James Gajewski and Sherry Pierce and Keating, {Michael J.}",
year = "1999",
month = "10",
day = "1",
doi = "10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O",
language = "English (US)",
volume = "86",
pages = "1216--1230",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Primary refractory and relapsed adult acute lymphoblastic leukemia

T2 - Characteristics, treatment results, and prognosis with salvage therapy

AU - Thomas, Deborah A.

AU - Kantarjian, Hagop

AU - Smith, Terry L.

AU - Koller, Charles

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Giles, Francis J.

AU - Gajewski, James

AU - Pierce, Sherry

AU - Keating, Michael J.

PY - 1999/10/1

Y1 - 1999/10/1

N2 - BACKGROUND. Relapses continue to be problematic for adults with acute lymphoblastic leukemia (ALL). New therapies generally are first tested in the salvage setting prior to incorporation into frontline regimens. Defining the prognosis at relapse (or at failure of induction) and subsequently predicting outcome would be useful to select the population in whom to test new strategies, rather than attempting traditional reinduction therapy. METHODS. Between March 1980 and March 1997, 314 eligible adults with primary refractory (24%) or primary relapsed (76%) ALL were treated with various chemotherapy or stem cell transplantation (SCT) regimens. The Cox proportional hazards model was used to assess biologic factors and disease history in relation to survival. RESULTS. A complete remission (CR) was achieved in 97 patients (31%), 21% died prior to a response, and 49% were refractory to salvage therapy. Of the 76 patients refractory to induction therapy for their de novo ALL, 26 patients (34%) achieved a CR with salvage therapy. The median overall CR duration was 6 months. The median overall survival was 5 months; 24% of the patients were alive at 1 year, and the projected survival at 5 years was 3%. Nineteen patients were alive at the time of last follow-up, 10 with 6 weeks to 10 years of continuous CR from the time of their first salvage therapy. SCT consolidation in second CR was performed in 25% of patients; 28% of those who received allogeneic SCT remain in continuous CR at 4 months, 2 1/2 years, 3 1/2 years, and 10 years, whereas all 8 who received autologous SCT have relapsed. Favorable factors for longer survival by multivariate analysis were age

AB - BACKGROUND. Relapses continue to be problematic for adults with acute lymphoblastic leukemia (ALL). New therapies generally are first tested in the salvage setting prior to incorporation into frontline regimens. Defining the prognosis at relapse (or at failure of induction) and subsequently predicting outcome would be useful to select the population in whom to test new strategies, rather than attempting traditional reinduction therapy. METHODS. Between March 1980 and March 1997, 314 eligible adults with primary refractory (24%) or primary relapsed (76%) ALL were treated with various chemotherapy or stem cell transplantation (SCT) regimens. The Cox proportional hazards model was used to assess biologic factors and disease history in relation to survival. RESULTS. A complete remission (CR) was achieved in 97 patients (31%), 21% died prior to a response, and 49% were refractory to salvage therapy. Of the 76 patients refractory to induction therapy for their de novo ALL, 26 patients (34%) achieved a CR with salvage therapy. The median overall CR duration was 6 months. The median overall survival was 5 months; 24% of the patients were alive at 1 year, and the projected survival at 5 years was 3%. Nineteen patients were alive at the time of last follow-up, 10 with 6 weeks to 10 years of continuous CR from the time of their first salvage therapy. SCT consolidation in second CR was performed in 25% of patients; 28% of those who received allogeneic SCT remain in continuous CR at 4 months, 2 1/2 years, 3 1/2 years, and 10 years, whereas all 8 who received autologous SCT have relapsed. Favorable factors for longer survival by multivariate analysis were age

KW - Acute lymphoblastic leukemia

KW - Prognostic factors

KW - Refractory

KW - Relapse

KW - Second induction

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0033214233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033214233&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O

DO - 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O

M3 - Article

VL - 86

SP - 1216

EP - 1230

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -